
Black patients who sought outpatient care for COVID-19 between January and July 2022 were 36% less likely than white patients to receive the antiviral pill Paxlovid, while Hispanic patients were 30% less likely than non-Hispanic patients to receive the treatment, according to a study released today by the Centers for Disease Control and Prevention, based on sites participating in the National Patient-Centered Clinical Research Network.